Medical Marijuana, Inc.’s investment company Axim Biotech receives approval from medical ethical committee to begin IBS trial for CBD product.
Medical Marijuana, Inc., the first-ever publicly traded cannabis company in the United States, announced that its major investment company Axim Biotechnologies, Inc. received approval from the Medical Ethical Committee (METC) of Wageningen University in The Netherlands to begin a study on patients suffering from irritable bowel syndrome (IBS) with the Axim’s product CanChew Plus cannabidiol (CBD)-containing chewing gum.
“We congratulate Axim on yet another step forward toward full clinical trials on cannabis-based treatments,” said Dr. Stuart Titus, CEO of Medical Marijuana Inc. “With the global treatment market for irritable bowel syndrome estimated to grow in value to $1.5 billion by 2023, cannabis-based products like CanChew Plus can provide viable solutions for patients suffering from some of the most common of functional gastrointestinal disorders.”
“It is the goal of our family of companies and for Axim to help people suffering from various gastrointestinal disorders with no effective remedies such as IBD and Crohn’s disease. Positive outcomes from these type of studies can help in the immediate need to enter trials for inflammatory bowel disease (IBD) and Crohn’s disease.”
METC at Wageningen University is an institutional approval board that is compliant with the Ethical Principles for Medical Research adopted at the 18th World Medical Association (WMA) General Assembly in Helsinki, Finland, in June 1964.
Wageningen University is a world-class education and research institute in the field of life sciences, agricultural and environmental science, and the only university in The Netherlands to focus on the theme of “healthy food and living environment.” According to the Times Higher Education World University Rankings, Wageningen is the best university in The Netherlands and No. 1 worldwide in agriculture and forestry for 2016 on the QS World University Rankings.
Filed Under: Drug Discovery